<DOC>
	<DOCNO>NCT02548351</DOCNO>
	<brief_summary>The primary objective study evaluate effect Obeticholic Acid treatment compare placebo 1 ) histological improvement 2 ) liver-related clinical outcome patient non-cirrhotic nonalcoholic steatohepatitis ( NASH ) liver fibrosis .</brief_summary>
	<brief_title>Randomized Global Phase 3 Study Evaluate Impact NASH With Fibrosis Obeticholic Acid Treatment</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>1 . Histologic evidence NASH upon central read liver biopsy obtain 6 month Day 1 define presence 3 key histological feature NASH score least 1 combine score 4 great possible 8 point accord NASH CRN criterion . 2 . Histologic evidence fibrosis stage 2 ( perisinusoidal portal/periportal ) stage 3 ( bridge fibrosis ) define NASH CRN score fibrosis , Histologic evidence fibrosis stage 1a stage 1b ( mild moderate , zone 3 perisinusoidal ) define NASH CRN score fibrosis accompany ≥1 follow risk factor : Obesity ( BMI ≥30 kg/m2 ) Type 2 diabetes diagnose per 2013 American Diabetes Association criterion ( hemoglobin A1c [ HbA1c ] ≥6.5 % , fast plasma glucose ≥126 mg/dL , 2hour plasma glucose ≥200 mg/dL oral glucose tolerance test , random plasma glucose ≥200 mg/dL ) ALT &gt; 1.5× upper limit normal ( ULN ) . 3 . For subject historical biopsy , either take stable dos TZDs/glitazones vitamin E 6 month Day 1 . 4 . Stable body weight ( ie , vary &gt; 10 % least 3 month ) Day 1 . 5 . Age ≥18 year . 6 . Female subject childbearing potential must use ≥1 effective method contraception study 30 day follow last dose investigational product . Effective method contraception consider list : Barrier method , ie , condom ( male female ) spermicide diaphragm spermicide Intrauterine device Vasectomy ( partner ) Hormonal ( eg , contraceptive pill , patch , intramuscular implant injection ) Abstinence ( define refrain heterosexual intercourse ) . 7 . Must provide write informed consent agree comply study protocol . 1 . Current history significant alcohol consumption period 3 consecutive month within 1 year Screening ( significant alcohol consumption define 2 units/day female 4 units/day male , average ) . 2 . Prior ( point ) plan ( study period ) ileal resection , prior ( within 5 year Screening ) plan ( study period ) bariatric surgery ( eg , gastric band , gastroplasty , rouxenY gastric bypass ) . 3 . HbA1c &gt; 9.5 % within 60 day Day 1 . 4 . Evidence form know chronic liver disease include : Positive test result Screening hepatitis B surface antigen ( hBsAg ) Active hepatitis C virus ( HCV ) infection ( positive HCV ribonucleic acid [ RNA ] Screening ) history positive HCV RNA test result PBC , PSC , autoimmune hepatitis , overlap syndrome Alcoholic liver disease Wilson 's disease , hemochromatosis , iron overload Alpha1antitrypsin ( A1AT ) deficiency define diagnostic feature liver histology ( confirm A1AT level lower limit normal [ LLN ] exclusion Investigator 's discretion ) Prior know druginduced liver injury within 5 year Day 1 Known suspect HCC History liver transplant , current placement liver transplant list , MELD score &gt; 12 . 5 . Histological presence cirrhosis . 6 . Total bilirubin &gt; 1.5 mg/dL ( subject Gilbert 's syndrome may enrol despite total bilirubin level &gt; 1.5 mg/dL conjugate bilirubin &lt; 1.5× ULN ) . 7 . AST ALT ≥10× ULN , international normalize ratio ( INR ) &gt; 1.5 , serum creatinine ≥1.5 mg/dL . 8 . Creatine phosphokinase &gt; 5x ULN . 9 . Platelet count &lt; 100 000/mm3 . 10 . LDL ≥190 mg/dL already stable dose statin therapy ≥30 day Screening . 11 . Inability safely undergo liver biopsy . 12 . History biliary diversion . 13 . Known positivity human immunodeficiency virus infection . 14 . Subjects recent history ( within 1 year Day 1 ) significant atherosclerotic cardiovascular disease ( myocardial infarction , unstable angina , acute coronary syndrome , cerebrovascular accident [ stroke ] , cerebrovascular ischemia , transient ischemic attack , peripheral vascular disease require intervention ) . Such subject may identify different mean , include limited , abnormal ECG , history plan cardiovascular intervention coronary revascularization ( eg , percutaneous coronary intervention coronary artery bypass graft ) , coronary angioplasty , stenting , carotid atherectomy , placement cardiac pacemaker defibrillator . • Controlled hypertension without recent manifestation significant atherosclerotic cardiovascular disease placement cardiac pacemaker defibrillator reason atherosclerotic cardiovascular disease ( eg , treatment atrial fibrillation subsequent nodal ablation ) exclusionary . 15 . Other medical condition may diminish life expectancy &lt; 2 year , include know cancer ( except carcinoma situ stable , relatively benign carcinoma ) . 16 . Known substance abuse year Screening . 17 . Pregnancy , plan pregnancy , potential pregnancy ( ie , unwillingness use effective birth control study ) , current plan breast feeding . 18 . Participated clinical research study investigational product evaluate treatment diabetes , weight loss , NASH 6 month Day 1 . 19 . Received investigational product evaluate treatment diabetes , weight loss , NASH Screening Day 1 , within 30 day Day 1 , within 5 halflives compound ( whichever longer ) Day 1 . 20 . Previous exposure OCA . 21 . Mental instability incompetence , validity inform consent ability compliant study , uncertain . 22 . History know suspect clinically significant hypersensitivity OCA component . 23 . Any condition , opinion Investigator , would impede compliance hinder completion study . 24 . Acute cholecystitis acute biliary obstruction . 25 . BMI &gt; 45 kg/m2 least 1 follow comorbidities : Hypertension blood pressure ≥140/90 mmHg &lt; 60 year , ≥150/90 mmHg ≥60 year , antihypertensive medication Hyperlipidemia define LDL cholesterol ≥160 mg/dL , total cholesterol ≥200 mg/dL , lipid lower medication Type 2 diabetes per 2013 American Diabetes Association criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non Alcoholic Steatohepatitis , fatty liver disease , NASH</keyword>
</DOC>